Annual CFO
-$18.29 M
+$25.75 M+58.46%
December 31, 2023
Summary
- As of February 12, 2025, QNCX annual cash flow from operations is -$18.29 million, with the most recent change of +$25.75 million (+58.46%) on December 31, 2023.
- During the last 3 years, QNCX annual CFO has risen by +$32.53 million (+64.00%).
- QNCX annual CFO is now -86.14% below its all-time high of -$9.83 million, reached on December 31, 2017.
Performance
QNCX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$7.26 M
+$1.48 M+16.92%
September 30, 2024
Summary
- As of February 12, 2025, QNCX quarterly cash flow from operations is -$7.26 million, with the most recent change of +$1.48 million (+16.92%) on September 30, 2024.
- Over the past year, QNCX quarterly CFO has dropped by -$1.18 million (-19.45%).
- QNCX quarterly CFO is now -277.14% below its all-time high of -$1.93 million, reached on September 30, 2018.
Performance
QNCX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$30.43 M
-$2.44 M-8.73%
September 30, 2024
Summary
- As of February 12, 2025, QNCX TTM cash flow from operations is -$30.43 million, with the most recent change of -$2.44 million (-8.73%) on September 30, 2024.
- Over the past year, QNCX TTM CFO has dropped by -$12.14 million (-66.36%).
- QNCX TTM CFO is now -857.82% below its all-time high of -$3.18 million, reached on March 31, 2018.
Performance
QNCX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
QNCX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +58.5% | -19.4% | -66.4% |
| 3 y3 years | +64.0% | -19.4% | -66.4% |
| 5 y5 years | -56.4% | -19.4% | -66.4% |
QNCX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +70.9% | -103.4% | +54.9% | -68.6% | +53.5% |
| 5 y | 5-year | at high | +70.9% | -103.4% | +58.7% | -68.6% | +53.5% |
| alltime | all time | -86.1% | +70.9% | -277.1% | +58.7% | -857.8% | +53.5% |
Quince Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.26 M(-16.9%) | -$30.43 M(+8.7%) |
| Jun 2024 | - | -$8.74 M(+4.6%) | -$27.99 M(+21.3%) |
| Mar 2024 | - | -$8.35 M(+37.4%) | -$23.08 M(+26.2%) |
| Dec 2023 | -$18.29 M(-58.5%) | -$6.08 M(+26.2%) | -$18.29 M(+1.3%) |
| Sep 2023 | - | -$4.82 M(+25.9%) | -$18.05 M(-9.4%) |
| Jun 2023 | - | -$3.83 M(+7.2%) | -$19.93 M(-36.8%) |
| Mar 2023 | - | -$3.57 M(-38.8%) | -$31.52 M(-28.4%) |
| Dec 2022 | -$44.04 M(-30.0%) | -$5.83 M(-12.9%) | -$44.04 M(-16.3%) |
| Sep 2022 | - | -$6.70 M(-56.6%) | -$52.62 M(-16.8%) |
| Jun 2022 | - | -$15.41 M(-4.2%) | -$63.27 M(-3.3%) |
| Mar 2022 | - | -$16.09 M(+11.6%) | -$65.41 M(+3.9%) |
| Dec 2021 | -$62.93 M | -$14.42 M(-16.9%) | -$62.93 M(+1.8%) |
| Sep 2021 | - | -$17.34 M(-1.3%) | -$61.79 M(+8.7%) |
| Jun 2021 | - | -$17.56 M(+29.0%) | -$56.82 M(+5.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$13.61 M(+2.5%) | -$53.65 M(+5.6%) |
| Dec 2020 | -$50.82 M(+52.7%) | -$13.28 M(+7.3%) | -$50.82 M(+4.8%) |
| Sep 2020 | - | -$12.37 M(-14.0%) | -$48.49 M(+8.0%) |
| Jun 2020 | - | -$14.39 M(+33.5%) | -$44.92 M(+21.9%) |
| Mar 2020 | - | -$10.78 M(-1.6%) | -$36.84 M(+10.7%) |
| Dec 2019 | -$33.28 M(+184.5%) | -$10.95 M(+24.5%) | -$33.28 M(+26.5%) |
| Sep 2019 | - | -$8.80 M(+39.3%) | -$26.30 M(+35.4%) |
| Jun 2019 | - | -$6.32 M(-12.5%) | -$19.43 M(+23.5%) |
| Mar 2019 | - | -$7.22 M(+81.6%) | -$15.73 M(+34.5%) |
| Dec 2018 | -$11.70 M(+19.0%) | -$3.97 M(+106.4%) | -$11.70 M(+51.5%) |
| Sep 2018 | - | -$1.93 M(-26.5%) | -$7.72 M(+33.2%) |
| Jun 2018 | - | -$2.62 M(-17.5%) | -$5.80 M(+82.5%) |
| Mar 2018 | - | -$3.18 M | -$3.18 M |
| Dec 2017 | -$9.83 M | - | - |
FAQ
- What is Quince Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Quince Therapeutics?
- What is Quince Therapeutics annual CFO year-on-year change?
- What is Quince Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Quince Therapeutics?
- What is Quince Therapeutics quarterly CFO year-on-year change?
- What is Quince Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Quince Therapeutics?
- What is Quince Therapeutics TTM CFO year-on-year change?
What is Quince Therapeutics annual cash flow from operations?
The current annual CFO of QNCX is -$18.29 M
What is the all time high annual CFO for Quince Therapeutics?
Quince Therapeutics all-time high annual cash flow from operations is -$9.83 M
What is Quince Therapeutics annual CFO year-on-year change?
Over the past year, QNCX annual cash flow from operations has changed by +$25.75 M (+58.46%)
What is Quince Therapeutics quarterly cash flow from operations?
The current quarterly CFO of QNCX is -$7.26 M
What is the all time high quarterly CFO for Quince Therapeutics?
Quince Therapeutics all-time high quarterly cash flow from operations is -$1.93 M
What is Quince Therapeutics quarterly CFO year-on-year change?
Over the past year, QNCX quarterly cash flow from operations has changed by -$1.18 M (-19.45%)
What is Quince Therapeutics TTM cash flow from operations?
The current TTM CFO of QNCX is -$30.43 M
What is the all time high TTM CFO for Quince Therapeutics?
Quince Therapeutics all-time high TTM cash flow from operations is -$3.18 M
What is Quince Therapeutics TTM CFO year-on-year change?
Over the past year, QNCX TTM cash flow from operations has changed by -$12.14 M (-66.36%)